New Endocrine Drugs - USI · New Endocrine Drugs Empagliflozin and Lingagliptin (Glyxambi®) •...
9
The JAMA Network JAMA.20K;31t(5);5O7-52O. dOi:IO.t001.|ama.2013 28-M2? 20H Hypertension Cii,.,i.>li:ifi '.Viiv/jiincut AlgoirtJunSBP indicates Systolic blood pi angiotensin-camfiningenzyme; ARB.BngtotMldn pBC4j%H MOCfcw; and CCB, calcil : Report From the New Endocrine Drugs Empagliflozin and Lingagliptin (Glyxambi®) • Combination sodium-glucose co- transporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor • Indication: - Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes - Not for treatment of type 1 DM - Has not been studied in patients with hx of pancreatitis *.
Transcript of New Endocrine Drugs - USI · New Endocrine Drugs Empagliflozin and Lingagliptin (Glyxambi®) •...
The JAMA Network
JAMA.20K;31t(5);5O7-52O. dOi:IO.t001.|ama.2013 28-M2?
20H Hypertension Cii,.,i.>li:ifi '.Viiv/jiincut AlgoirtJunSBP indicates Systolic blood piangiotensin-camfiningenzyme; ARB.BngtotMldn pBC4j%H MOCfcw; and CCB, calcil
: Report From the
New Endocrine Drugs
Empagliflozin and Lingagliptin(Glyxambi®)• Combination sodium-glucose co-
transporter 2 (SGLT2) inhibitor anddipeptidyl peptidase-4 (DPP-4) inhibitor
• Indication:
- Adjunct to diet and exercise to improveglycemic control in adults with type 2diabetes
- Not for treatment of type 1 DM
- Has not been studied in patients with hx ofpancreatitis *.